This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-HLA-A2.1 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the HLA-A2.1 as well as the biological activity of IL2. In vitro analysis revealed that the IL2-FuP supported mainly proliferation and lymphokine-activated killer cell activity. IL2 fused immunocytokine significantly accumulated in the tumor, which led to retardation of tumor growth. This immunocytokine was designed for treating tumor.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-500 | Recombinant Anti-human HLA-A Antibody | WB, FC, FuncS | IgG |
MOB-2307MZ | Recombinant Mouse Anti-Human HLA-A Antibody (clone 9.M.208), Biotin-Conjugated | FC, ICC/IF | Mouse antibody |
HPAB-1096WJ | Mouse Anti-HLA-A Recombinant Antibody (HPAB-1096WJ) | ELISA | Mouse IgG1 |
ZG-1014F | Mouse Anti-HLA-A Antibody (clone BRA-23/9) | FC, IHC-Fr | Mouse IgG2a |
VS3-CJ359 | Mouse Anti-HLA-A Recombinant Antibody (clone W6132) | IF, FC | Mouse IgG2a, κ |
There are currently no Customer reviews or questions for ACFP-SH015. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.